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that, in Switzerland, as compared with placebo, progesterone
use increased the risk for spontaneous delivery within 14 days
and preterm birth at <37 weeks of gestation.3
Suhag et al1 might argue that the 4P trial was not included in
their review because progesterone was givenwithin 24 hours of
the start of acute tocolysis and therefore could not be consid-
ered as “maintenance” tocolysis. The study medication was
initiated after stabilization of the patient (diminution/arrest
of uterine contractions with acute tocolysis) and continued
until 36 weeks of gestation or delivery, if it happened before.
There were only 9 women who delivered within the ﬁrst
48 hours. Analysis that included only women who were sta-
bilized for at least 48 hours showed the same result (ie, pro-
gesterone did not decrease the risk of preterm delivery).2,4
Regarding the studies included in the review of Suhag
et al,1 they were all small (between 52 and 183 cases), and
only 2 were compared with placebo. Metaanalysis is of great
help in clinical practice, especially when large studies are not
available. The decision to exclude trials should be based on
strict inclusion criteria. We do not understand why Suhag
et al decided not to include the largest randomized trial on
vaginal progesterone in women with preterm labor to be
published until now.
On the basis of existing literature, progesterone should not
be given as maintenance tocolysis in women with preterm
labor. Beneﬁts have not been found, and harms have not been
excluded. New large, randomized, and placebo-controlled
studies will be soon published and will help in drawing
conclusions. -
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Thank you for the interest in our metaanalysis.1 We
congratulate Dr Martinez de Tejada et al2 on their recent
publication on vaginal progesterone for prevention of pre-
term birth (4P trial).
One of the most important aspects of a metaanalysis is the
inclusion criteria. Strict inclusion criteria are needed to
reduce both clinical and statistical heterogeneity. Moreover,
the protocol of every metaanalysis should be decided a priori
before the data extraction and should not be modiﬁed. These
are key elements that are needed to evaluate the reliability of
a metaanalysis. In 2011, the ﬁrst international prospective
register of systematic reviews (PROSPERO) was launched by
the Centre for Reviews and Dissemination, University of
York, UK. All journals should encourage prospective regis-
tration of all planned systematic review protocols because
it helps to promote transparency and safeguards against
publication bias and duplication of reviews. Recently, pre-
ferred reporting items for systematic review and meta-
analysis guidelines for protocols have also been published.3
In our protocol, which is registered with PROSPERO
(CRD42014013706), we a priori decided to include all pub-
lished randomized controlled trials (RCTs) of singleton ges-
tations that had arrested preterm labor (PTL) and were
randomized to maintenance tocolysis treatment with either
vaginal progesterone or control.1
As Martinez de Tejada et al2 knows well, we tried our best
to include their trial in our metaanalysis, as we can conﬁrm
by the several emails that we exchanged directly with her early
in 2015. In their RCT,2 vaginal progesterone was given within
48 hours of the start of acute tocolysis and was used as an
additional agent with primary tocolysis, not as maintenance
tocolysis,4 which was also pointed out by the Commentary to
their study.5 Indeed, in their RCT, vaginal progesterone ap-
pears to be used for women both who had (perhaps) arrested
PTL and those who did not.2 Maintenance tocolysis means
that preterm contractions have resolved, at least 48 hours
have elapsed from presentation, and steroids have been given;
now the patient is being considered for discharge. This is not
at all what happened in the 4P RCT. The 4P authors did not
mention whether the study subjects were assessed for arrested
PTL before randomization and allocation of vaginal proges-
terone vs placebo. For these reasons, including their RCT
would have been methodologically incorrect, which would
have compromised the reliability of our metaanalysis on
maintenance tocolysis. We had already explained this well in
several emails to Martinez de Tejada, who was aware. There
are indeed other RCTs that use progesterone as an additionalSEPTEMBER 2015 American Journal of Obstetrics & Gynecology 439
Letters to the Editors ajog.orgagent to primary tocolysis.6 The RCT by Martinez de Tejada
et al2 can, if desired, possibly be combined with this RCT and
other future similar trials.
After carefully reviewing the 4P trial, we agree with
Dr Norwitz’s commentary5 to this trial and then his reply
again to Martinez de Tejada et al that the 4P study is un-
derpowered to conclude that there is no beneﬁt of vaginal
progesterone as a tocolytic, given, among other reasons, the
fact that they did not reach their own precalculated sample
size. Unlike these authors, we did not make any absolute and
deﬁnitive clinical recommendations in our study. In our
metaanalysis, we concluded that “Maintenance tocolysis with
vaginal progesterone is associated with prevention of PTB,
signiﬁcant prolongation of pregnancy, and lower neonatal
sepsis. However, given the frequent lack of blinding and the
generally poor quality of the trials, we do not currently
suggest a change in clinical care of women with arrested PTL.
We suggest instead well-designed placebo-controlled ran-
domized trials to conﬁrm the ﬁndings of our meta-analysis.”1
Once again, congratulations to Martinez de Tejada et al for
their 4P trial. We look forward to more excellent work and
publications from their group. -
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2015.05.038Skin incision for cesarean delivery in morbidly obese womenTO THE EDITORS: In reference to the recent dialogue
generated by Marrs et al1 in the article associated with
complications found on cesarean deliveries on obese partu-
rients and the letter by Gordon and Welch.2 We would like to
bring to the attention of the authors that Joel-Cohen3 in 1954
proposed a detailed manner to enter the abdominal cavity in
obese women with the use of a transverse incision 3 cm below
the level of the anterior superior iliac spines. This detailed
and elegant description is convincing. Krebs and Helmkamp4
further described transverse incisions below and above the
umbilicus in obese female patients with marked advantages
for the supraumbilical incision. These techniques must be
reviewed thoroughly by the teams who are planning ran-
domized trials that will involve cesarean deliveries in
morbidly or extremely obese patients. -
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